WIL goes Midwest to increase service offering
Through the addition of these services, which include preclinical and clinical immunoanalytical and bioassay techniques, WIL believes it will be better equipped to serve its clients with small molecule and biologics development services.
These services should prove complementary to those already offered by WIL, allowing the company to offer a more comprehensive package to clients.
Commenting on this, Christopher Chengelis, vice president and chief scientific officer at WIL, said: “Midwest BioResearch rounds out our service offerings, particularly in the areas of genetic toxicity and biotech and clinical support capabilities.”
These expertise present little overlap with WIL, which provides contract research services for companies needing toxicology assistance in areas including neuro, inhalation, and intravenous.
In addition WIL can already offer clients safety pharmacology, bioanalytical chemistry and metabolism services. As well as giving WIL a more rounded service offering the union will provide the company with the staff to execute these tasks.
WIL is retaining the services of Michael Schlosser, president and founder of Midwest BioResearch, who will continue to run the site Skokie, Illinois.
In addition to employing Schlosser WIL has stated it is keen to retain other staff at Midwest, with Chengelis saying: “We also benefit from a world-class staff with significant pharmaceutical and biotechnology industry experience and the addition of a program services consulting group.”
